Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in xenotransplantation.

L E Diamond1

  • 1Nextran, Inc., 303B College Road East, Princeton, NJ, USA. ldiamond@nextran.com

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning methods to support personalized neuromusculoskeletal modelling.

Biomechanics and modeling in mechanobiology·2020
Same author

Individuals with mild-to-moderate hip osteoarthritis walk with lower hip joint contact forces despite higher levels of muscle co-contraction compared to healthy individuals.

Osteoarthritis and cartilage·2020
Same author

Hip joint moments during walking in people with hip osteoarthritis: a systematic review and meta-analysis.

Osteoarthritis and cartilage·2018
Same author

A systematic review and evidence synthesis of qualitative studies to identify primary care clinicians' barriers and enablers to the management of osteoarthritis.

Osteoarthritis and cartilage·2016
Same author

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

Urology·2005
Same author

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

International journal of impotence research·2004
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Pig organs show promise for transplantation due to donor shortages. Overcoming hyperacute rejection is key to advancing xenotransplantation and utilizing these animal organs in humans.

Area of Science:

  • Transplantation immunology
  • Xenotransplantation research

Background:

  • Organ transplantation is the primary treatment for organ failure but faces donor shortages.
  • Pigs are the most suitable animal donors for xenotransplantation.
  • Hyperacute rejection, mediated by antibodies and complement, is an immediate barrier.

Purpose of the Study:

  • To review strategies preventing hyperacute rejection in xenotransplantation.
  • To investigate the immunological barriers of acute vascular rejection.
  • To identify key factors for successful xenotransplantation.

Main Methods:

  • Review of experimental models for xenograft rejection.
  • Analysis of immunological mechanisms in hyperacute rejection.
  • Exploration of humoral immune responses in acute vascular rejection.

Related Experiment Videos

Main Results:

  • Strategies to prevent hyperacute rejection have shown success in experimental models.
  • Acute vascular rejection is the subsequent immunological barrier.
  • This rejection phase is antibody-mediated.

Conclusions:

  • Preventing hyperacute rejection allows focus on acute vascular rejection.
  • Controlling antibody synthesis is crucial for successful xenotransplantation.
  • Further research into humoral immunity is needed to overcome xenotransplantation barriers.